Where can Revumenib-Revuforj be purchased?

Revumenib (Revumenib)-Revuforj is an innovative oral targeted drug developed by Syndax Pharmaceuticals. It is mainly used to treat patients with acute leukemia who carry KMT2A (also known as MLL) gene rearrangements or NPM1 mutations. This type of leukemia includes types such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), which usually have a poor prognosis and a high relapse rate. The development of Revimenib marks a major breakthrough in molecular targeted therapy of leukemia. It brings new treatment hope to patients with drug resistance or relapse by blocking key oncogenic signaling pathways.

In terms of pharmacological mechanism, Revemenib is a menin inhibitor. It blocks the transcriptional drive and proliferation signals of cancer cells by specifically inhibiting the interaction between menin and KMT2A protein. This mechanism is completely different from traditional chemotherapy or radiotherapy. It has the advantages of precise target, less toxic and side effects, and significant potential for long-term efficacy. The US FDA has approved Revuforj in 2024 for the treatment of relapsed or refractory acute leukemia associated with KMT2A rearrangement or NPM1 mutation. It is the first approved drug in the menin inhibitor class.

Currently, Revimenib has not been officially launched in mainland China, so domestic patients cannot directly obtain the original drug in hospitals or pharmacies. If you really need to use the drug, you usually need to obtain the US version of the original drug through overseas channels. Common purchasing channels include: international pharmacy authorization platforms, designated suppliers of overseas medical institutions, and medical intermediaries with formal cross-border pharmaceutical service qualifications. These channels generally provide two specifications:110mg 30 tablets and 160mg 30 tablets. It is expensive, with the overall cost of approximately RMB 200,000 or more (the specific price fluctuates with the exchange rate), and the transportation and customs declaration procedures are relatively complicated.

It is worth noting that if patients plan to purchase through overseas channels, they should ensure that they choose a legally authorized drug supplier and be guided by a doctor with hematology experience. SinceRevumenib involves complex gene target detection, it is recommended to conduct molecular typing confirmation before treatment to determine whether it belongs to the applicable population.

Reference materials:https://www.drugs.com/monograph/revumenib.html